DecisionHealth, DecisionHealth - 2004 Issue 2 (February)
Medicare assigns new HCPCS for anti-diarrhea drug, octreotide
Subscribe or sign in to view the full article.
Article Overview
This article reviews Medicare coding changes affecting gastroenterology and oncology drug billing, including new HCPCS assignments, payment-limit updates, carrier coverage references, and associated diagnosis-code groupings. It is aimed at coders, billers, and reimbursement staff who need to track annual HCPCS changes and related payer guidance for drug claims.
Why This Topic Matters
Annual Medicare code updates can affect how drugs are reported and reimbursed, as well as which diagnosis codes are recognized by carriers for payment. The article helps readers identify the broad coverage and coding changes relevant to these drugs without relying on the full premium text.
Article Sections
-
Medicare assigns new HCPCS for anti-diarrhea drug, octreotide
Introduces the Medicare update and the general context for the HCPCS changes discussed in the article.
-
Octreotide HCPCS updates and carrier diagnosis references
Covers the Medicare HCPCS changes, payment-limit information, and payer references tied to octreotide-related claims.
-
Oxaliplatin HCPCS update and related diagnosis codes
Summarizes the HCPCS change for the related oncology drug and the associated carrier coverage context for colorectal cancer claims.
What You Will Learn
- How the article frames Medicare HCPCS updates for selected drugs
- What types of payer and carrier references are discussed
- Which broad diagnosis-code groupings are mentioned in relation to coverage
- How the article connects drug coding changes to gastroenterology and oncology billing topics
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement staff
- Practice managers
- Gastroenterology billing teams
- Oncology billing teams
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com